World Health Organization Raises Alert Over Acute Scarcity of Obesity Injections
Under a tenth of individuals that would benefit from GLP-1 drugs including Wegovy can access them, warns the WHO as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for more widespread and fairer access to GLP-1 medication.
According to estimates, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a chronic disease that can be addressed with comprehensive and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major barriers to broad availability to the treatments that can assist patients in reducing significant weight, notes the body.
Skinny Jab Shortage
Even under the present most favorable outlook, the supply of GLP-1 therapies could only cover around 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges governments and firms to increase access, by strategies including licensing agreements.
A patent on a key compound – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Work
These medications imitate a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so individuals eat less.
People commonly see weight reduction in the initial weeks of commencing the regular doses.
Research points to people may regain a significant portion a year later of discontinuing the medication, because their typical food cravings return.
Being overweight or obese raises your risk for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
